SLC22A1 and ovarian cancer: Here, we propose that the expression level of OCT1 could dictate the added benefits for ovarian cancer patients receiving DOX together with the paclitaxel-platinum regimen, or to substitute paclitaxel with DOX in light of the observation that OCT1 can also transport paclitaxel36.